東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Hepatocellular carcinoma and liver d...

Boley, Patricia Anne.

Linked to FindBook

Google Book

Amazon

博客來

Hepatocellular carcinoma and liver disease in mice with inducible oncogene expression.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Hepatocellular carcinoma and liver disease in mice with inducible oncogene expression./
Author:	Boley, Patricia Anne.
Description:	200 p.
Notes:	Source: Dissertation Abstracts International, Volume: 71-03, Section: B, page: 1635.
Contained By:	Dissertation Abstracts International71-03B.
Subject:	Health Sciences, Oncology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3400102
ISBN:	9781109663723

Hepatocellular carcinoma and liver disease in mice with inducible oncogene expression.
Boley, Patricia Anne.

Hepatocellular carcinoma and liver disease in mice with inducible oncogene expression. - 200 p.

Source: Dissertation Abstracts International, Volume: 71-03, Section: B, page: 1635.

Thesis (Ph.D.)--The University of Wisconsin - Madison, 2009.

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Genetic alterations suspected of playing a role in HCC onset and progression have been the subject of intense investigation. Transgenic mouse models allow specific targeting of selected oncogenes using cell- or tissue-specific promoters. I used the tetracycline inducible system to systematically introduce oncogenic manipulations at defined stages of growth into liver. Specifically, the inducible system allowed me to examine the effects of turning on oncogene expression in the adult liver rather than targeting expression throughout development, and to determine how focal rather than diffuse hepatocyte targeting influences cancer progression. Several new transgenic lines of mice expressing inducible oncogenes were characterized. c-Myc or c-Myc plus TGF-alpha caused hyperplasia and progression to neoplasia as early as 4 and 3 months of age, respectively. c-Myc-induced liver disease in our model progressed more rapidly than previous in constitutively-expressed models, even though the level of c-Myc expression was lower in the inducible than in the constitutively expressed model. I examined gene expression patterns using microarray and found that constitutively expressed c-Myc and inducible c-Myc caused different patterns of gene expression with little in common.

ISBN: 9781109663723Subjects--Topical Terms:

1018566
Health Sciences, Oncology.

Hepatocellular carcinoma and liver disease in mice with inducible oncogene expression.
LDR:03451nam 2200289 4500 001 1403510
005 20111118095944.5
008 130515s2009 ||||||||||||||||| ||eng d
020 $a 9781109663723
035 $a (UMI)AAI3400102
035 $a AAI3400102
040 $a UMI $c UMI
100 1 $a Boley, Patricia Anne. $3 1682775
245 1 0 $a Hepatocellular carcinoma and liver disease in mice with inducible oncogene expression.
300 $a 200 p.
500 $a Source: Dissertation Abstracts International, Volume: 71-03, Section: B, page: 1635.
500 $a Adviser: Eric P. Sandgren.
502 $a Thesis (Ph.D.)--The University of Wisconsin - Madison, 2009.
520 $a Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Genetic alterations suspected of playing a role in HCC onset and progression have been the subject of intense investigation. Transgenic mouse models allow specific targeting of selected oncogenes using cell- or tissue-specific promoters. I used the tetracycline inducible system to systematically introduce oncogenic manipulations at defined stages of growth into liver. Specifically, the inducible system allowed me to examine the effects of turning on oncogene expression in the adult liver rather than targeting expression throughout development, and to determine how focal rather than diffuse hepatocyte targeting influences cancer progression. Several new transgenic lines of mice expressing inducible oncogenes were characterized. c-Myc or c-Myc plus TGF-alpha caused hyperplasia and progression to neoplasia as early as 4 and 3 months of age, respectively. c-Myc-induced liver disease in our model progressed more rapidly than previous in constitutively-expressed models, even though the level of c-Myc expression was lower in the inducible than in the constitutively expressed model. I examined gene expression patterns using microarray and found that constitutively expressed c-Myc and inducible c-Myc caused different patterns of gene expression with little in common.
520 $a I next evaluated the effect of neighboring normal cells on the ability of genetically altered cells to initiate growth in a quiescent liver environment, testing whether genetically altered hepatocytes over-expressing c-Myc or TGF-alpha or expressing mutant H-ras or beta-catenin, alone or in combination, can initiate growth when turned on as clusters or as single cells in a quiescent liver. No oncogene combination could transform all transplant foci into altered hepatocyte foci, indicating that progression required donor cells to accumulate additional changes. When oncogene expression was restricted to single cells in non-transgenic recipients, only oncogene combinations initiated neoplastic progression.
520 $a I examined the liver's capacity for lesion reversal late in the progression stage of carcinogenesis, and explored changes in gene expression patterns and molecular mechanisms that accompany phenotypic reversion of HCC when transgene expression was silenced. Silencing oncogene expression near end stage liver disease almost completely reversed liver lesions, indicating that continued oncogene expression is necessary for oncogene-induced growth disruption.
590 $a School code: 0262.
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0992
710 2 $a The University of Wisconsin - Madison. $3 626640
773 0 $t Dissertation Abstracts International $g 71-03B.
790 1 0 $a Sandgren, Eric P., $e advisor
790 $a 0262
791 $a Ph.D.
792 $a 2009
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3400102